David E. Gauden, D.Phil.
David was a co-founder of our sister company Blue Earth Diagnostics. As Chief Scientific Officer he was instrumental in building the company from a start-up in 2014 to a successful leader in nuclear medicine and molecular imaging and its acquisition by Bracco Imaging in 2019. David led the spin-out of 黑料老司机s in 2021. Prior to founding Blue Earth Diagnostics, David was Product Leader for Oncology Molecular Imaging at GE Healthcare. With more than 25 years in the radiopharmaceuticals industry, David has deep experience across the field. He has a degree in microbiology and microbial technology from Warwick University and a doctorate in radiochemistry from Oxford University.
%20HR%20009C.jpeg)
Dr. Daniel Stevens
Dan is a board certified (UK) pharmaceutical physician with a dedication to translational science and drug development. His industry career is underpinned by NHS clinical academic training and he is a Fellow of the Faculty of Pharmaceutical Medicine at the Royal College of Physicians. His experience in industry has been focused on novel oncology drug development from lead identification through to NDA. His expertise lies in clinical development and medical affairs as they relate to oncology and urology. Most recently, he has developed specific experience in targeted radioligand therapy. Leading, or being part of, development teams which have taken 4 novel molecules into the clinic in the US and Europe, successfully navigating manufacturing, operational and regulatory challenges.
Chelsea Roche
Chelsea is an intellectual property lawyer with commercial, corporate, litigation and governance experience, and is dual qualified as an English Solicitor and Australian Legal Practitioner. Previously she was General Counsel and a core member of the Executive team for Blue Earth Diagnostics and has considerable experience supporting translational research and funding activity. She started her career as a Nuclear Medicine Technologist and has several years鈥� experience at international law firms advising life sciences clients and serves as Trustee for the Institute of Physics and Engineering in Medicine and is a member of the BioIndustry Association Intellectual Property Advisory Committee.
.jpg)
Bradley Waldron
Brad is a CMC specialist with deep experience in development, manufacturing, and supply of radiopharmaceuticals. He was previously CMC Lead for diagnostic and therapeutic radiopharmaceuticals at IPSEN/OctreoPharm Sciences. Brad has a doctorate in Chemistry from Durham University and completed post-doctoral studies in radiopharmaceutical development at Johannes Gutenberg University.
Robert Dann
Robert has worked on developing novel therapeutics, diagnostics and applications for cancer care for much of his career, primarily in global product strategy and strategic marketing roles. He started his healthcare career at AstraZeneca where he took three cancer therapeutics each to >$1B revenues. At GE Healthcare he led global oncology marketing and drove the launches of several new oncology diagnostics. More recently he has held oncology strategy and leadership roles at IBM Watson Health and at start-up biotechs. He has also participated in several corporate acquisitions and investment rounds. He has an MBA from Columbia University and a Master鈥檚 in Russian Civilization from the University of Chicago.
David was a co-founder of our sister company Blue Earth Diagnostics. As Chief Scientific Officer he was instrumental in building the company from a start-up in 2014 to a successful leader in nuclear medicine and molecular imaging and its acquisition by Bracco Imaging in 2019. David led the spin-out of 黑料老司机s in 2021. Prior to founding Blue Earth Diagnostics, David was Product Leader for Oncology Molecular Imaging at GE Healthcare. With more than 25 years in the radiopharmaceuticals industry, David has deep experience across the field. He has a degree in microbiology and microbial technology from Warwick University and a doctorate in radiochemistry from Oxford University.
Dan is a board certified (UK) pharmaceutical physician with a dedication to translational science and drug development. His industry career is underpinned by NHS clinical academic training and he is a Fellow of the Faculty of Pharmaceutical Medicine at the Royal College of Physicians. His experience in industry has been focused on novel oncology drug development from lead identification through to NDA. His expertise lies in clinical development and medical affairs as they relate to oncology and urology. Most recently, he has developed specific experience in targeted radioligand therapy. Leading, or being part of, development teams which have taken 4 novel molecules into the clinic in the US and Europe, successfully navigating manufacturing, operational and regulatory challenges.
Chelsea is an intellectual property lawyer with commercial, corporate, litigation and governance experience, and is dual qualified as an English Solicitor and Australian Legal Practitioner. Previously she was General Counsel and a core member of the Executive team for Blue Earth Diagnostics and has considerable experience supporting translational research and funding activity. She started her career as a Nuclear Medicine Technologist and has several years鈥� experience at international law firms advising life sciences clients and serves as Trustee for the Institute of Physics and Engineering in Medicine and is a member of the BioIndustry Association Intellectual Property Advisory Committee.
Brad is a CMC specialist with deep experience in development, manufacturing, and supply of radiopharmaceuticals. He was previously CMC Lead for diagnostic and therapeutic radiopharmaceuticals at IPSEN/OctreoPharm Sciences. Brad has a doctorate in Chemistry from Durham University and completed post-doctoral studies in radiopharmaceutical development at Johannes Gutenberg University.
Robert has worked on developing novel therapeutics, diagnostics and applications for cancer care for much of his career, primarily in global product strategy and strategic marketing roles. He started his healthcare career at AstraZeneca where he took three cancer therapeutics each to >$1B revenues. At GE Healthcare he led global oncology marketing and drove the launches of several new oncology diagnostics. More recently he has held oncology strategy and leadership roles at IBM Watson Health and at start-up biotechs. He has also participated in several corporate acquisitions and investment rounds. He has an MBA from Columbia University and a Master鈥檚 in Russian Civilization from the University of Chicago.
